Table 1.

Efficacy of streptozocin- or temozolomide-based regimens in metastatic pancreatic endocrine tumors

Study	Regimen	Patients, n	Tumor response rate, %	Median overall survival, mo
Prospective studies
Moertel et al., 1992 [21]	Chlorozotocin	33	30	18.0
	Fluorouracil + streptozocin	33	45	16.8
	Doxorubicin + streptozocin	36	69	26.4
Ramanathan et al., 2001 [49]	Dacarbazine	50	34	19.3
Kulke et al., 2006 [24]	Temozolomide + thalidomide	11	45	NR
Kulke et al., 2006 [25]	Temozolomide + bevacizumab	17	24	NR
Retrospective studies
Kouvaraki et al., 2004 [22]	Streptozocin + doxorubicin + fluorouracil	84	39	37
Isacoff et al., 2006 [27]	Temozolomide + capecitabine	17	59	8.9
Ekeblad et al., 2007 [26]	Temozolomide (single agent)	12	8	NR
Strosberg et al., 2008 [28]	Temozolomide + capecitabine	17	71	NR

NR—not reported.